RESEARCH ARTICLE

The OPRM1 gene and interactions with the 5-HT1a gene regulate conditioned pain modulation in fibromyalgia patients and healthy controls

Jeanette Tour1,2,3*, Angelica Sandström1,2, Diana Kadetoff1,4, Martin Schalling5, Eva Kosek1,2,6

1 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 2 Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden, 3 Department of Oncology, Blekinge Hospital, Karlskrona, Sweden, 4 Stockholm Spine Center, Löwenströmska Hospital, Upplands Väsby, Sweden, 5 Department of Molecular Medicine and Surgery, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden, 6 Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

* Jeanette.tour@ki.se

Abstract

Fibromyalgia (FM) patients have dysfunctional endogenous pain modulation, where opioid and serotonergic signaling is implicated. The aim of this study was to investigate whether genetic variants in the genes coding for major structures in the opioid and serotonergic systems can affect pain modulation in FM patients and healthy controls (HC). Conditioned pain modulation (CPM), evaluating the effects of ischemic pain on pressure pain sensitivity, was performed in 82 FM patients and 43 HC. All subjects were genotyped for relevant functional polymorphisms in the genes coding for the μ-opioid receptor (OPRM1, rs1799971), the serotonin transporter (5-HTT, 5-HTTLPR/rs25531) and the serotonin 1a receptor (5-HT1a, rs6295). Results showed the OPRM1 G-allele was associated with decreased CPM. A significant gene-to-gene interaction was found between the OPRM1 and the 5-HT1a gene. Reduced CPM scores were seen particularly in individuals with the OPRM1 G/*5-HT1a CC genotype, indicating that the 5-HT1a CC genotype seems to have an inhibiting effect on CPM if an individual has the OPRM1 G-genotype. Thus, regardless of pain phenotype, the OPRM1 G-allele independently as well as with an interaction with the 5-HT1a gene influenced pain modulation. FM patients had lower CPM than HC but no group differences were found regarding the genetic effects on CPM, indicating that the results reflect more general mechanisms influencing pain modulatory processes rather than underlying the dysfunction of CPM in FM. In conclusion, a genetic variant known to alter the expression of, and binding to, the my-opioid receptor reduced a subject’s ability to activate descending pain inhibition. Also, the results suggest a genetically inferred gene-to-gene interaction between the main opioid receptor and a serotonergic structure essential for 5-HT transmission to modulate pain inhibition. The results in this study highlight the importance of studying joint synergistic and antagonistic effects of neurotransmitter systems in regard to pain modulation.
Introduction

Fibromyalgia (FM) is characterized by generalized long-term pain, often along with non-restorative sleep, fatigue and cognitive impairment like memory loss [1–3]. The pain in FM is regarded as nociplastic [4–6], as FM patients fulfill the nociplastic pain criteria [7] based on the characteristic pain hypersensitivity [8,9]. Furthermore, dysfunctional descending pain inhibition, i.e., reduced exercise-induced hypoalgesia (EIH) [10,11] and conditioning pain modulation (CPM) [12,13] has been reported in FM patients.

Pain modulatory processes involve several neuromodulators including opioids and serotonin (5-HT). In healthy subjects, endogenous opioid as well as 5-HT signaling has been implicated to affect CPM [14,15]. In FM patients, indirect evidence of increased opioid- and reduced 5-HT metabolism has been described [16,17]. There is also evidence of interactions between opioid and serotonergic signaling. Animal studies have shown that 5-HT1a agonists can prevent and reverse opioid-induced hyperalgesia [18]. Also, the efficacy of an opioid agonist was increased in individual carriers of a serotonergic genotype proposed to reduce 5-HT signaling [19]. We recently showed that, by genetic association, increased endogenous opioid tone along with lower serotonergic signaling produced more profound EIH [11], a paradigm similar to but not identical with CPM [20,21]. To test the generalizability of this finding, we here study a different paradigm of endogenous pain inhibition, i.e. CPM, and in a different cohort of FM patients and healthy controls (HC).

The aim of this study was to assess the influence of specific pain related genetic variants on CPM. More specifically, the single nucleotide polymorphism (SNP) rs1799971 in the OPRM1 gene, regulating the expression, availability, as well as the activation of the μ-opioid receptors (MOR) [22]. Individuals with the G-genotype (A/G or G/G) are proposed to have increased receptor affinity for β-endorphins [23], thus increased endogenous opioid efficacy compared with the homozygous AA-genotype, however, there are conflicting results [24]. A meta-analysis concluded recently that individuals with the OPRM1 G-genotype have reduced analgesic efficacy of opioid drugs [25]. Also, this variant has been shown to influence cerebral processing during evoked pain regardless of pain phenotype [26] and has been linked to reduced cerebral MOR availability [27]. Moreover, we jointly studied two functional polymorphisms (5-HTTLPR and rs25531) in the serotonin transporter (5-HTT) gene SLC6A4. Together they alter the degree of gene expression and functionally divide individuals into groups of high, intermediate or low expression of the 5-HTT [14,28], which have been associated with CPM efficacy in HC [14]. Lastly, the SNP rs6295 in the HTR1A gene, regulates the expression of the 5-HT1a receptor [29]. Individuals with the 5-HT1a G-genotype (C/G or GG) are associated with having reduced 5-HT signaling compared with the homozygous CC-genotype [30,31] and increased sensitivity to suprathreshold pain [32].

Based on our previous findings [11] we hypothesized that individuals with OPRM1 G-genotype in combination with the 5-HTT low expression or 5-HT1a G-genotype have a more pronounced CPM, and vice versa, and that this will be seen regardless of baseline pain level, i.e., in FM patients and HC alike.

Materials and method

Participants

The current study forms part of a larger project, see study plan https://osf.io/8zqak [33,34]. Study participants were recruited by local news advertisement. FM patients were evaluated by an experienced physician with a standardized interview and palpation of tender points to verify both the American College of Rheumatology 1990 criteria for FM [35] and the newer 2010 criteria.
criteria [36]. Inclusion criteria included female sex, right handedness and age between 20–60 years. Exclusion criteria for FM patients and HC were high blood pressure (>160/90), painful osteoarthritis, other causes of pain than FM for FM patients or any pain rated as more than 20/100 VAS (visual analog scale) for HC, other severe somatic or psychiatric disorder, addiction disorder, pregnancy, severe obesity (BMI > 35), smoking, medication with antidepressants or anticonvulsants, and inability to refrain from analgetics, anti-inflammatory drugs or hypnotics for 48 hours before participation in the study. HC were screened by telephone before their visit. A total of 117 FM patients and 45 HC were screened for participation. Subjects were excluded for not meeting the inclusion/exclusion criteria (FM n = 17, HC n = 1) and for declining participation (FM n = 14). 4 FM patients and 1 HC failed to complete the CPM assessment. Thus, data for the analysis included 82 FM patients and 43 HC. One subject was not included in the genetic analyses due to failed genotyping. All participants were Caucasian women. They were given verbal and written information and gave written informed consent in accordance with the Declaration of Helsinki. The study was reviewed and approved by the Swedish Ethical Review Authority board (permit 2014/1604-31/1) before the study began.

Procedures

Questionnaires. All participants completed standardized and validated questionnaires concerning health status and quality of life. The questionnaires analyzed in the present study are Hospital Anxiety and Depression Scale (HADS), Short-Form-36 Bodily Pain Scale (SF-36 BP), and for FM patients the Fibromyalgia Impact Questionnaire (FIQ). HADS consists of 2 subscales assessing depressive (HAD-D) and anxiety (HAD-A) symptoms in nonpsychiatric patients. Each subscale comprises of 7 items with accumulated scores between 0 and 21. Cut-off scores of above 8 can be regarded as the presence of anxiety and depressive disease [37]. The SF-36 BP, a 2-item subscale within the Short Form (SF-36), was chosen to assess pain severity and pain over time (4 weeks). The raw scores are transformed into a 0 to 100 scale, where lower score indicate more pain symptoms [38]. The FIQ is a questionnaire assessing symptoms and disability related to FM. It consists of 20 items with scores ranging from 0 to 100, where higher values indicates a poorer state of health due to FM [39].

Pressure Pain Thresholds (PPTs). To assess pain sensitivity pressure algometry (Algometer, Somedic Sales, Sweden) was used with a probe area of 1 cm², manual pressure perpendicular to the skin was applied with an increase pressure rate of 50kPa/s. The subjects then pressed a response button at the slightest sensation of pain. PPTs were assessed bilaterally on 4 sites corresponding to the tender points of the ACR 1990 criteria for FM classification, namely musculus trapezius, lateral epicondyle of the humerus, musculus gluteus maximus, and medial proximal fat pad of knee. The assessments were conducted by two test investigators who were jointly trained to perform assessments comparably (JT, AS).

Conditioned Pain Modulation (CPM). CPM is a reliable method for assessing endogenous pain modulatory processes [40]. In this study, CPM was assessed with a tourniquet test for each individual. The subjects were comfortably seated upright on a stretcher with the backrest raised to approximately 50 degrees and resting their left arm on an armrest. A baseline assessment of pain sensitivity was done before the start of the tourniquet test, with 2 PPTs at the subject’s right thigh (m. quadriceps). The left arm was raised vertically for 1 minute to drain the arm for venous blood, then a blood pressure cuff was put on the left upper arm and inflated to 200 mmHg. The subject then lifted a 1 kg weight with their left underarm extensor muscles. The subjects continuously rated their experienced pain on a VAS (0-100mm) scale. When they rated 50 mm they were told to stop lifting the weight and endure the conditioning pain. The examiner started assessing PPTs with the algometer at the subjects right (contralateral) m. quadriceps. PPTs were assessed
continuously with a minimum of 20 seconds between assessments until the subject asked to stop or for a maximum of 4 minutes. A final post CPM assessment of PPT was made 5 minutes after the end of the conditioning stimulus at *m.*quadriceps (Fig 1).

**Genotyping.** The SNPs in this study were chosen based on a priori hypotheses based on existing literature. To be consistent with previous research, the genotypes of the rs1799971 (118A>G, N40D) of the OPRM1 gene and the C(-1019)G 5-HT1a promoter polymorphism of the HTR1A gene coding for the 5-HT1a receptor were dichotomized into major allele homozygotes and minor allele carriers [41-43]. The 5-HTT gene (SLC6A4) includes the functional polymorphism 5-HTTLPR, which consists of an L allele and an S allele, where the S-allele is associated with reduced 5-HTT expression [44]. Moreover, the functional polymorphism rs25531 containing an *A*-allele and a *G*-allele has been shown to further modulate the efficacy of 5-HTTLPR, the minor *G*-allele reduces gene expression to S-allele levels [28]. Given this proposed efficacy and in line with our previous studies [11,19], we examined 5-HTTLPR/rs25531 jointly, referred to as the triallelic 5-HTTLPR. This approach results in functional division of the study subjects into having high (L*L*), intermediate (L*L* and L*S*) and low (S*S* and S*L*) expression of 5-HTT.

For genotyping, saliva samples (Oragene G500) were collected from all subjects. For the polymorphisms rs1799971 (OPRM1) and rs6296 (5-HT1a), genotyping was performed using TaqMan SNP genotyping assays and ABI 7900 HT instrument (Applied Biosystems (ABI), Foster City, CA). Polymerase chain reactions (PCRs), with a total volume of 5 mL, were performed in 384-well plates containing 2.5 mL Universal Master Mix (UMM) and 5 ng dried-down genomic DNA per well. The PCR amplification protocol includes 2 holds, 50˚C for 2 minutes and denaturation at 95˚C for 10 minutes, followed by 45 cycles for rs6296 and 50 cycles for rs1799971 at 92˚C for 15 seconds and 60˚C for 1 minute. For the genotyping of the triallelic 5-HTTLPR, 2 fragments, 487 bp (short) and 530 bp (long), were amplified by PCRs. Each PCR reaction contained 50 ng DNA, 0.2 mM deoxynucleotide triphosphate (dNTP), 0.4 mMof primer 17P-3F, 0.4 mM primer 17P- 3R, 0.05 mL Qiagen HotStar Polymerase, 1 M Q-solution, and finally 1x buffer. Samples were amplified on Biorad Tettrade (BIORAD, Hercules, CA) with an initial denaturation for 10 minutes at 95˚C followed by 33 cycles consisting of denaturation for 30 seconds at 95˚C, annealing for 30 seconds at 57˚C and elongation for 5 minutes at 72˚C, and finally followed by another elongation step for 5 minutes at 72˚C. Eight microliters of the PCR reactions were separated for 2 hours at 100 V by gel electrophoresis in TBE buffer on a 2.5% agarose gel containing GelRed and visualized using ultraviolet light. To determine the rs25531, 10 mL of the PCR product was digested with 0.1 mL MSP1 (New England Biolabs, Ipswich, MA) and 1 mL buffer per sample for 12 hours at 37˚C. The MSP1 restriction enzyme breaks the 59-C/CGG9 sequence that gives a fragment of 342 base pairs.
one of 127 and finally one of 62 base pairs which constitutes the LA allele, whereas the 298, 127, and 62 base pairs is the SA allele, the 173, 166, 127, and 62 base pairs for the LG allele, and finally the 166, 130, 127, and 62 for the SA allele. Fragments were run on a 4% agarose gel (3% normal agarose and 1% low melting agarose) containing GelRed initially for 15 minutes at 70 V followed by 2 more hours at 100 V. The gels were then visualized with ultraviolet light.

Statistics

CPM score and normalization of PPTs. To assess the associations between functional genetic polymorphisms and CPM, a CPM score was calculated, as the difference between the end value and the baseline value divided by the baseline value [11,14]. A positive CPM score indicates increased pain inhibition, whereas a negative CPM score indicates facilitation, i.e. increased pressure pain sensitivity during the conditioning stimulation (tourniquet test). In order to control for the evident interindividual differences in pain sensitivity, i.e., PPTs [45] in the assessments of CPM, the scores were normalized by dividing the PPT at each time point with the individuals first PPT at baseline (before the CPM assessment) [46]. A value over 1 indicates pain inhibition, i.e. decreased sensitivity to pressure pain during conditioning stimulation. Normalized PPTs were used to analyze the temporal aspects of CPM.

Statistical analyses. All analyses were made using SPSS Statistics, version 27 (SPSS Inc, Chicago, IL). Data were reported as mean with standard deviation and graphs as mean with error bars of 1 standard error of the mean. Graphs visualizing normalized PPTs were adjusted by adding a coefficient so that the baseline value corresponded to 1. Reported p-values were two-sided and p < 0.05 was considered statistically significant. Allelic deviation from Hardy-Weinberg equilibrium was tested with Chi-square test, and genotype frequencies were analyzed with the Fisher exact test and Chi-square test. The Shapiro–Wilk test was used to assess deviations from a normally distributed sample. To assess differences in pain sensitivity, CPM score, normalized PPTs, contraction time, number of PPT assessments and test leader differences, Students t-test and the Mann–Whitney U test was used.

The overall effects of gene-to-gene interactions were analyzed by univariate ANOVAs, with CPM score as the dependent variable, and genotypes as independent variables (OPRM1 AA/∗G, 5HT1a CC/∗G, 5-HTT low/intermediate/high), and age, HAD-A, and HAD-D as covariates. Post-hoc tests were performed with univariate ANOVAs and Students t-test.

The assessment of the temporal aspects of CPM were analyzed by repeated measures analysis of variance (ANOVA) with the within-subject factor TIME (normalized PPTs; baseline, start, middle, end and after 5 minutes), age as a covariate and the between subject factor GROUP (FM/HC) and GENOTYPE (OPRM1 AA/∗G) in separate analyses. Post-hoc analysis was made with the Mann-Whitney U test. When the assumption of sphericity was violated the Greenhouse-Geisser correction was used. To assert possible methodological differences between the groups, the model was repeated adding the covariates for the length in time of the tourniquet test and number of PPT assessments.

Multivariate ANOVA was used to assess whether the different genotypes affected symptom parameters. The analysis was performed in FM patients with the dependent variables FIQ, HAD-D, HAD-A, average PPT, and SF-36 BP, the independent variables OPRM1, 5-HTT, and 5-HT1a, and age as a covariate.

Results

Participant and genotype characteristics

Patient characteristics for FM patients and HC are presented in Table 1. FM patients had significantly lower average PPT, indicating increased pain sensitivity compared to HC.
(p < 0.001) and reduced CPM score (p < 0.001) indicating a dysfunction of conditioning pain modulation. Allele frequencies were in Hardy-Weinberg equilibrium (rs1799971 X2 (1) = 3.34 p = 0.067, rs6295 X2 (1) = 0.45 p = 0.50, 5-HTTLPR X2 (1) = 0.25 p = 0.61). Genotype frequencies, presented in Table 2, were similar in both groups for all genotypes. The results did not differ between test leaders for average PPT (p = 0.17) or CPM score (p = 0.91) indicating similar methodology across the study group. The FM patient group had shorter mean tourniquets assessment time (start after rating > 50 mm VAS) with 192 seconds compared to 220 seconds in the HC group. However, given the lower PPTs in the FM group both groups had an equal number of PPT assessments.

| Table 1. Descriptives of study population. | FM patients (N = 82) | HC (N = 43) | p-value |
| --- | --- | --- | --- |
| Age (years) | 47.2 ± 7.8 | 48.3 ± 7.7 | p = 0.47 |
| BMI (kg/m²) | 26.2 ± 3.8 | 22.7 ± 2.4 | < 0.001 |
| FM duration (months) | 121 ± 88 | NA | |
| Tenderpoint count* | 17 (range 11–18) | NA | |
| Widespread Pain Index* | 15 (range 9–19) | NA | |
| Symptom Severity Score* | 10 (range 5–12) | NA | |
| Average PPT (kPa) | 150 ± 63 | 318 ± 109 | < 0.001 |
| Average VAS | 58 ± 22 | 4 ± 6 | < 0.001 |
| CPM score | -0.03 | 0.20 | p = 0.005 |

Questionnaires:

| | FM patients (N = 82) | HC (N = 43) | p-value |
| --- | --- | --- | --- |
| FIQ | 62.9 ± 16.5 | NA | |
| HAD-D | 7.2 ± 4.0 | 1.1 ± 1.5 | < 0.001 |
| HAD-A | 7.8 ± 4.2 | 3.1 ± 3.0 | < 0.001 |
| SF-36 BP | 31.3 ± 14.1 | 89.4 ± 12.5 | < 0.001 |

Number of PPT assessments 11.5 ± 3.2 11.3 ± 2.5 p = 0.72

Tourniquet time (seconds) 192 ± 51 220 ± 35 p < 0.001

Numbers reported as means ± SD unless otherwise indicated. FM = fibromyalgia, HC = healthy controls, NA = not applicable, BMI = body mass index, PPT = pressure pain threshold, VAS = visual analog scale, FIQ = Fibromyalgia impact questionnaire, HAD-D = Hospital anxiety and depression scale—depression, HAD-A = Hospital anxiety and depression scale—anxiety, SF-36 BP = 36-item short form—bodily pain.

*p median value.

https://doi.org/10.1371/journal.pone.0277427.t001

| Table 2. Genotype frequencies of the polymorphisms rs1799971 (OPRM1), rs6296 (5-HT₁A) and the triallelic 5-HTT for the whole group, as well as fibromyalgia (FM) patients and healthy controls (HC) separately. |
| --- | --- | --- |
| | Whole group | FM patients | HC |
| | N = 124 | N = 82 | N = 43 |
| OPRM1 | | | |
| AA | 96 | 77.4 | 60 | 74.1 | 36 | 83.7 |
| (rs1799971) G-carrier | 28 | 22.6 | 21 | 25.9 | 7 | 16.3 | p = 0.26 |
| 5-HT₁A | | | |
| CC | 26 | 21.0 | 16 | 19.8 | 10 | 23.3 |
| (rs6296) G-carrier | 98 | 79.0 | 65 | 80.2 | 33 | 76.7 | p = 0.65 |
| 5-HTT | | | |
| High | 20 | 16.1 | 12 | 15.2 | 8 | 19.5 |
| Intermediate | 58 | 46.8 | 38 | 48.1 | 20 | 48.8 |
| Low | 42 | 33.9 | 29 | 36.7 | 13 | 31.7 | p = 0.78 |

Genotype frequencies did not differ between the FM and HC group (p-values). Call rate > 99% for OPRM1 and 5-HT1a and 96% for 5-HTT.

https://doi.org/10.1371/journal.pone.0277427.t002
Associations of CPM score with the gene OPRM1

As hypothesized, no statistically significant interactions were found between group (FM, HC) and genetic polymorphisms regarding the CPM score, indicating similar genetic effects regardless of baseline pain level. When both groups were analyzed jointly, a statistically significant effect of OPRM1 (df = 1, F = 5.7, p = 0.019) was found for the CPM score. More specifically, individuals with OPRM1 AA-genotype had higher CPM scores compared to the G-genotype (mean CPM scores: OPRM1 AA 0.085 (SD 0.49), G-genotype -0.093 (SD 0.45), which indicates reduced ability in individuals with OPRM1 G-genotype to activate descending pain inhibition (Fig 2A). Post hoc testing of each group separately revealed significant effects of the OPRM1 genotype on CPM score in FM patients, (df = 1, F = 4.17, p = 0.045), with reduced CPM score in FM patients carrying the OPRM1 G-allele (mean CPM scores: OPRM1 AA 0.011 (SD 0.54), G-genotype -0.18 (SD 0.47), while no significant effect was seen in HC (Fig 2B). Regarding the serotonergic genes, no significant effects on CPM score were found for 5-HT1a or 5-HTT, respectively.

Gene-to-gene interactions

There was a gene-to-gene interaction between OPRM1 and 5-HT1a (df = 1, F = 5.38, p = 0.022). Post hoc analyses revealed that individuals with 5-HT1a CC genotype had better CPM score if they had the OPRM1 AA genotype compared with the OPRM1 G-genotype (p = 0.029), indicating better central pain inhibition with the genetic setup of 5-HT1a CC-genotype and OPRM1 AA-genotype (Fig 3). Also, there was a trend that individuals with
OPRM1 G-genotype and 5-HT1a G-genotype had higher CPM score compared with the 5-HT1a CC-genotype (CPM score CC: -0.43 (SD 0.52) and G -0.02 (SD 0.41); p = 0.065). Regarding the serotonergic genes, no significant interactions were found for 5-HT1a x 5-HTT nor for 5-HTT x OPRM1, and thus, no post hoc analyses were performed.

### Genetic effects on the temporal aspects of CPM

Regarding the effect of the genetic polymorphism in OPRM1 on normalized PPTs assessed over time there was a statistically significant effect of GENOTYPE (OPRM1 AA or G-genotype) (df = 1, F = 4.59, p = 0.034) and a significant GENOTYPE x TIME interaction (df = 3.11, F = 2.93, p = 0.032). Post-hoc analyses reveal that individuals with the OPRM1 G-genotype, compared to the AA-genotype, had significantly lower CPM at start (p = 0.035) as well as after the conditioning stimulus (p = 0.008), revealing a reduced ability to activate descending pain pathways.
inhibition, with the effect persisting up to 5 minutes after the assessment. The data visualized in Fig 4 indicate that the effect of reduced CPM in OPRM1 G-genotype individuals is similar in FM patients and HC (Fig 4B and 4C). However, post hoc tests failed to show significance when FM and HC were analyzed separately, as power is reduced.

**Assessment of temporal aspects of CPM in FM patients compared to HC**

Differences in normalized PPTs over time (baseline, start, mid, end and after 5 minutes) between FM patients and HC were assessed by repeated measures ANOVA. A significant TIME x GROUP interaction (df = 3.16, F = 3.48, p = 0.014) was found. Post-hoc analysis revealed a statistically significant group difference at the end of the CPM paradigm (p < 0.001), indicating better functioning pain inhibitory processes in HC compared to FM patients (Fig 5). Moreover, FM patients had reduced pain sensitivity after 5 minutes with a group mean below the mean PPT at start, indicating pain facilitation after the CPM
assessment. This represents a statistically significant difference between the groups, where the HC group still showed activated pain inhibition (p = 0.041). As there was a significant group difference in the length of the CPM assessment, an additional model was used to control for this. However, no significant influence of the length of the CPM assessment was found (time x group df = 3.32, F = 3.70, p = 0.009 and time x length of CPM df = 3.32, F = 1.43 p = 0.23).

Associations between genetic polymorphisms and FM symptoms

There were no statistically significant effects of the assessed polymorphisms of OPRM1 or 5-HT1a regarding symptom severity (FIQ, HAD-A, HAD-D, SF36-BP) or pain sensitivity (average PPT). There was a significant effect of 5-HTT and an interaction between 5-HTT x 5-HT1a regarding HAD-D, i.e. assessment of depression, data reported elsewhere [47]. Also, a significant gene-to-gene interaction with HAD-D was found regarding 5-HTT x 5-HT1a x OPRM1 (F = 6.07, df = 1, p = 0.016).

Discussion

Here we examined the role of specific functional genetic polymorphisms acting on opioid and serotonergic signaling on CPM in healthy subjects and patients with FM. This is the first study to show that, by inferring from genotype, phenotypes of endogenous opioid signaling significantly influence descending pain modulation in humans as measured by CPM. More specifically, OPRM1 G-allele, mechanistically proposed to increase the affinity for β-endorphins [23], while reducing MOR expression and signaling [24] was associated with decreased CPM, i.e. a reduced ability to activate descending pain inhibition. Furthermore, there was a gene-to-gene
interaction between the OPRM1 and the 5-HT1a gene, revealing that the negative effects of the OPRM1 G-genotype on CPM were seen specifically in individuals with the 5-HT1a CC-genotype, which associated with increased 5-HT signaling mediated via the 5-HT1a receptor [48]. This interaction is in line with our hypothesis based on our previous report of genetic influence on pain modulation, where we showed gene interactions with a similar pattern during EIH, with carriers of the 5-HT1a CC/OPRM1 G-genotype exhibiting the lowest EIH [11]. Lastly, similar to the results from the previous EIH study, there were no differences between FM patients and HC regarding the effects of the genetic variants on pain modulatory processes. Thus, these results seem to reflect more general mechanisms influencing pain modulatory processes and not the underlying dysfunction of CPM in FM.

The effect of the MOR and the OPRM1 gene on CPM

The opioid system, and μ-opioid receptors in particular, is known to be involved in descending pain modulation. Here, we show that a genetic variant in the OPRM1 gene, coding for the μ-opioid receptor (MOR), independently influences the function of CPM. Individuals with the OPRM1 G-genotype had significantly poorer ability to activate descending pain modulation where endogenous opioids are engaged. In the literature, this genetic variant is proposed to mediate stronger binding of endogenous opioids to the μ-opioid receptor [23], suggesting an increase of function. However, it is well established that individuals with this variant require higher postoperative exogenous opioids for pain relief, instead suggesting a loss of function [25,49]. A study of opioid-naive healthy subjects showed that strong μ-opioid agonists potentiated CPM [50], while the opposite was seen in long-term opioid drug users who displayed less efficient CPM, suggesting a dampening effect on the endogenous pain modulatory system by longstanding exposure [51]. On a similar note, the OPRM1 G-allele has been proposed to exhaust the opioid system of a compensatory reaction to chronic exposure to opioid drugs [52] and could thus hypothetically be relevant for the shift from anti- to pronociceptive pain modulatory processes during long-term opioid exposure. Based on this, we hypothesize that the OPRM1 G-genotype plays a role in interindividual differences of endogenous opioid effect on CPM activation. Pecina et al demonstrated that carriers of the OPRM1 G-allele had reduced μ-opioid receptor availability in brain areas implicated in regulation of pain and affect [27]. Thus, the OPRM1 G-allele, favoring a higher MOR affinity for β-endorphins [23], could hypothetically have a negative impact on opioid signaling, due to lower availability of MOR. During the CPM assessment in the present study, a strong painful sensation was evoked by the conditioning stimulus (mean rating of worst pain was VAS 77/100) which most likely induced an immediate engagement of central endogenous opioids. Hypothetically, individuals with the OPRM1 G-allele would have a stronger initial binding of endogenous opioids to MOR leaving less receptors available to newly activate and initiate pain inhibition from antinociceptive neurons downstream, resulting in a loss of function of pain inhibition as reported here.

Compared to HC, FM patients have a reduced MOR binding capacity in brain regions implicated in pain regulation, including the opioid rich rostral anterior cingulate cortex (rACC) [53,54]. Importantly, lower MOR binding capacity was associated with reduced pain related activation of rACC in FM patients [55]. Moreover, FM patients display less functional connectivity between the rACC and other parts of the brain’s pain inhibitory network [56] as well as decreased cortical thickness of rACC, related to a longer duration of FM [57]. In analogy with our hypothesis regarding the OPRM1 polymorphism, Schrepf et al. (2016) proposed that initially high levels of endogenous opioids in FM patients [16] would cause downregulation and/or reduced affinity of MOR in the antinociceptive brain regions, thus explaining the failure to activate descending inhibitory mechanisms during pain stimulation in FM. In this
scenario, FM patients with the OPRM1 G-genotype would be expected to have a further reduction of MOR signaling during evoked pain, resulting in even less efficient descending pain inhibition. Indeed, FM patients in our study had reduced CPM compared to HC, as has been repeatedly reported previously [12,58], interestingly with the lowest CPM scores seen in FM patients carrying the OPRM1 G-allele (Fig 2B). Thus, the effect of the OPRM1 G-allele variant seems to exist regardless of baseline function of descending pain inhibition or the presence of a chronic pain condition.

Interaction between opioid and serotonergic genes on CPM

The opioid system interacts with the serotonergic pain regulatory system in an antagonistic, time- and state dependent way [59]. However, the specific effect of 5-HT1a on opioid mediated pain modulation is difficult to interpret. Stimulation of MOR give a first order analgesic effect, but can have a second order hyperalgesic effect, i.e. opioid-induced hyperalgesia, which in turn can be counteracted by stimulation with 5-HT1a agonists [18]. In fact, 5-HT1a agonists have the opposite profile to opioids, i.e., a first order pronociceptive, followed by a second order analgesic effect [60] and the 5-HT1a receptor is shown to mediate inhibition of pain [61]. Thus, the effects of 5-HT signaling on pain perception seem to depend on the state of the opioid system.

On a genetic level, the proposed mechanism of the 5-HT1a G-genotype is that it leads to a reduction in 5-HT transmission, as it yields upregulation of presynaptic inhibitory 5-HT1a auto-receptors in the raphe nuclei where 5-HT is synthesized, and downregulation of postsynaptic 5-HT1a receptors [48,62]. In this study, we found significant gene-to-gene interactions between genes coding for the 5-HT1a receptor and MOR. More specifically, individuals with 5-HT1a CC/OPRM1 G-genotype had significantly reduced CPM score, i.e. reduced ability to activate descending pain modulation, as compared to other genetic combinations. In fact, these two genotypes combined produced negative CPM scores, meaning pain facilitation during CPM. As described above, the OPRM1 G-genotype was in itself associated with a lower CPM score, but this effect was driven by individuals with genetically inferred increased 5-HT signaling and higher concentrations of postsynaptic 5-HT1a receptors. The latter is in accordance with the interactions between 5-HT1a agonists and opioids [18]. Furthermore, these data are in line with our previous report on these genes influence on EIH [11]. Interestingly, both methodologies, i.e. CPM and EIH, produced gene-to-gene interactions in the same direction based on proposed mechanisms of the opioid and 5-HT1a polymorphisms studied, and no difference was found based on baseline pain level (FM patients or HC).

Contrary to our findings during EIH [11], no statistically significant interactions between OPRM1 and 5-HTT affecting CPM were found. Previous studies regarding the effects of the 5-HTT polymorphism on CPM have shown inconsistent results. Healthy carriers of the low expressing 5-HTT polymorphism had reduced CPM affecting both mechanical- and heat pain stimuli when the tourniquet was used as conditioning stimulus [14], reduced CPM during cold pressor test as measured by non-painful heat stimuli but not painful heat stimuli [63], as well as normal CPM assessed by tonic heat stimuli during a cold pressor test, the latter was also seen in FM patients [58]. The inconsistent effects of the 5-HTT polymorphism on CPM may explain why we failed to reveal a 5-HTT and OPRM1 interaction in the current study.

Limitations

The main limitation of our study is that the effects of opioid and serotonergic signaling are inferred from genotypes in opioid and serotonergic genes. Therefore, we should not draw definite conclusions to underlying biological mechanisms. Nevertheless, genetic variability
influences pain phenotypes [64]. This method is well established in the literature and allows us to study pain regulation without pharmacological manipulation, which has an additive value to current knowledge of pain regulatory processes. Furthermore, as the analyses of the FM and HC groups separately are based on rather low sample sizes for the uncommon genotypes of the investigated genetic polymorphisms, the results must be regarded as exploratory and need to be reproduced in larger cohorts.

Conclusions

This is the first study to show that the gene OPRM1, coding for a main structure of endogenous opioid signaling, independently influences pain behavior without exogenous opioids being involved. More specifically, a polymorphism known to alter the expression of, and binding to, the μ-opioid receptor influences an individual’s ability to activate descending pain inhibition during ischemic pain. Furthermore, a gene-to-gene interaction was found showing that the OPRM1 G-genotype/5-HT1a CC-genotype conferred significantly reduced ability to activate descending pain modulation, as compared to other genetic combinations. The results revealed that the effect of the OPRM1 G-genotype on CPM was driven by individuals with genetically inferred higher 5-HT signaling and higher concentrations of postsynaptic 5-HT1a receptors. Interestingly, this gene-to-gene interaction is similar to our previous results from a study assessing EIH in HC and FM patients, thus validating the findings to, not only two different methodologies to activate descending pain inhibition, but also two different cohorts.

Acknowledgments

The authors thank the personnel at KIGene, Karolinska Institutet, Stockholm, Sweden for excellent collaboration and for performing the DNA extraction and genotyping, we also thank for the excellent patient recruitment and administrative support during this project.

Author Contributions

Conceptualization: Eva Kosek.
Data curation: Jeanette Tour, Angelica Sandström, Diana Kadetoff, Martin Schalling.
Formal analysis: Jeanette Tour.
Funding acquisition: Eva Kosek.
Investigation: Jeanette Tour.
Methodology: Jeanette Tour, Martin Schalling, Eva Kosek.
Project administration: Martin Schalling, Eva Kosek.
Resources: Martin Schalling, Eva Kosek.
Supervision: Eva Kosek.
Writing – original draft: Jeanette Tour, Eva Kosek.
Writing – review & editing: Jeanette Tour, Angelica Sandström, Diana Kadetoff, Martin Schalling, Eva Kosek.

References

1. Sumpton JE, Moulin DE. Fibromyalgia. Handbook of clinical neurology. 2014; 119:513–27. https://doi.org/10.1016/B978-0-7020-4086-3.00033-3 PMID: 24365316
2. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016; 46(3):319–29. https://doi.org/10.1016/j.semarthrit.2016.08.012 PMID: 27916278

3. Galvez-Sánchez CM, Reyes Del Paso GA. Diagnostic Criteria for Fibromyalgia: Critical Review and Future Perspectives. J Clin Med. 2020; 9(4). https://doi.org/10.3390/jcm9041219 PMID: 32340369

4. Bazzichi L, Giacomelli C, Consensi A, Giorgi V, Batticciotto A, Di Franco M, et al. One year in review 2020: fibromyalgia. Clin Exp Rheumatol. 2020; 38 Suppl 123(1):3–8. PMID: 32116216

5. Kosek E, Cohen M, Baron R, Gebhart GF, Mico JA, Rice AS, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016; 157(7):1382–6. https://doi.org/10.1097/j.pain.000000000000507 PMID: 26835783

6. Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet (London, England). 2021; 397(10289):2098–110. https://doi.org/10.1016/S0140-6736(21)00392-5 PMID: 34062144

7. Kosek E, Clauw D, Nijs J, Baron R, Gilron I, Harris RE, et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain. 2021. https://doi.org/10.1097/j.pain.0000000000002324 PMID: 33974577

8. Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain. 1996; 68(2–3):375–83. https://doi.org/10.1016/s0304-3959(96)03188-0 PMID: 9121827

9. Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016; 338:114–29. https://doi.org/10.1016/j.neuroscience.2016.06.006 PMID: 27291641

10. Lannersten L, Kosek E. Dysfunction of endogenous pain inhibition during exercise with painful muscles in patients with shoulder myalgia and fibromyalgia. Pain. 2010; 151(1):77–86. https://doi.org/10.1016/j.pain.2010.06.021 PMID: 20621420

11. Tour J, Lofgren M, Mannerkorpi K, Gerdle B, Larsson A, Palstam A, et al. Gene-to-gene interactions regulate endogenous pain modulation in fibromyalgia patients and healthy controls-antagonistic effects between opioid and serotonin-related genes. Pain. 2017; 158(7):1194–203. https://doi.org/10.1097/j.pain.000000000000896 PMID: 28282362

12. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain. 1997; 70(1):41–51. https://doi.org/10.1016/s0304-3959(96)03295-2 PMID: 9106808

13. Yarnitsky D. Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. Current opinion in anaesthesiology. 2010; 23(5):611–5. https://doi.org/10.1097/ACO.0b013e32833c348b PMID: 20543676

14. Lindstedt F, Berrebi J, Greayer E, Lonsdorf TB, Schalling M, Ingvar M, et al. Conditioned pain modulation is associated with common polymorphisms in the serotonin transporter gene. PLoS One. 2011; 6(3):e18252. https://doi.org/10.1371/journal.pone.0018252 PMID: 21464942

15. Ramaswamy S, Wodehouse T. Conditioned pain modulation-A comprehensive review. Neuropsychol Clin. 2020. https://doi.org/10.1016/j.neucli.2020.11.002 PMID: 33334645

16. Baraniuk JN, Whalen G, Cunningham J, Clauw DJ. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC musculoskeletal disorders. 2004; 5(1):48. https://doi.org/10.1186/1471-2474-5-48 PMID: 15588296

17. Russell IJ, Vaeryo H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis and rheumatism. 1992; 35(5):550–6. https://doi.org/10.1002/art.1780350509 PMID: 1374252

18. Colpaert FC, Deseure K, Stinus L, Adriaensen H. High-efficacy 5-hydroxytryptamine 1A receptor activation counteracts opioid hyperalldynia and affective conditioning. The Journal of pharmacology and experimental therapeutics. 2006; 316(2):892–9. https://doi.org/10.1124/jpet.105.095109 PMID: 16254131

19. Kosek E, Jensen KB, Lonsdorf TB, Schalling M, Ingvar M. Genetic variation in the serotonin transporter gene (5-HT1a) influences the analgesic response to the short acting opioid Remifentanil in humans. Mol Pain. 2009; 5:37. https://doi.org/10.1186/1744-8069-5-37 PMID: 19570226

20. Ellingson LD, Koltyn KF, Kim JS, Cook DB. Does exercise induce hypoalgesia through conditioned pain modulation? Psychophysiology. 2014; 51(3):267–76. https://doi.org/10.1111/psyp.12168 PMID: 24354707

21. Lemley KJ, Hunter SK, Bement MK. Conditioned pain modulation predicts exercise-induced hypoalgesia in healthy adults. Med Sci Sports Exerc. 2015; 47(1):176–84. https://doi.org/10.1249/MSS.000000000000381 PMID: 24870571
22. Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, et al. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? Journal of pain research. 2013; 6:331–53.

23. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opioid addiction. Proc Natl Acad Sci U S A. 1998; 95(16):9608–13. https://doi.org/10.1073/pnas.95.16.9608 PMID: 9689128

24. Oertel BG, Kettner M, Scholich K, Renné C, Roskamp B, Geisslinger G, et al. A common human micro-opioid receptor gene variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem. 2009; 284(10):6530–5. https://doi.org/10.1074/jbc.M807030200 PMID: 19116204

25. Zhang X, Liang Y, Zhang N, Yan Y, Liu S, Fengxi H, et al. The Relevance of the OPRM1 118A>G Genetic Variant for Opioid Requirement in Pain Treatment: A Meta-Analysis. Pain physician. 2019; 22(4):331–40.

26. Ellerbrock I, Sandström A, Tour J, Kadetoff D, Schalling M, Jensen KB, et al. Polymorphisms of the μ-opioid receptor gene influence cerebral pain processing in fibromyalgia. European journal of pain (London, England). 2021; 25(2):398–414. https://doi.org/10.1002/ejp.1680 PMID: 33064887

27. Pecina M, Love T, Stohler CS, Goldman D, Zubieta JK. Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2015; 40(4):957–65. https://doi.org/10.1038/npp.2014.272 PMID: 25930892

28. Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry. 11. England2006; p. 224–6. https://doi.org/10.1038/sj.mp.4001789 PMID: 16402131

29. Czesak M, Lemonde S, Peterson EA, Rogaeva A, Albert PR. Cell-specific repressor or enhancer activity of the 118A>G gene polymorphism in the human 5-HT1A receptor gene. Psychiatr Genet. 1999; 9(2):105–6. https://doi.org/10.1097/00041444-199906000-00010 PMID: 10412191

30. Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol. 2009; 88(1):17–31. https://doi.org/10.1016/j.pneurobiol.2009.01.009 PMID: 19428959

31. Wu S, Comings DE. A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr Genet. 1999; 9(2):105–6. https://doi.org/10.1097/00041444-199906000-00010 PMID: 10412191

32. Lindstedt F, Karshikoff B, Schalling M, Olgart Höglund C, Ingvar M, Lekander M, et al. Serotonin-1A receptor polymorphism (rs6295) associated with thermal pain perception. PLoS One. 2012; 7(8):e43221. https://doi.org/10.1371/journal.pone.0043221 PMID: 22952650

33. Fanton S, Sandström A, Tour J, Kadetoff D, Schalling M, Jensen KB, et al. The translocator protein gene is associated with endogenous pain modulation and the balance between glutamate and GABA in fibromyalgia and healthy subjects: a multimodal neuroimaging study. Pain. 2021.

34. Sandström A, Ellerbrock I, Tour J, Kadetoff D, Jensen KB, Kosek E. Neural correlates of conditioned pain responses in fibromyalgia subjects indicate preferential formation of new pain associations rather than extinction of irrelevant ones. Pain. 2020; 161(9):2079–88. https://doi.org/10.1007/j.pain.0000000000001907 PMID: 32379218

35. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and rheumatism. 1990; 33(2):160–72. https://doi.org/10.1002/art.1780330203 PMID: 2306288

36. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. The Journal of rheumatology. 2011; 38(6):1113–22. https://doi.org/10.3899/jrheum.100594 PMID: 21285161

37. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. Journal of psychosomatic research. 2002; 52(2):69–77. https://doi.org/10.1016/s0022-3991(01)00296-3 PMID: 11832252

38. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis care & research. 2011; 63 Suppl 11:S240–52.
40. Kennedy DL, Kemp H, Ridout D, Yarnitsky D, Rice ASC. Reliability of conditioned pain modulation: a systematic review. Pain. 2016; 157(11):2410–9. https://doi.org/10.1097/j.pain.0000000000000689 PMID: 27559835

41. Lemoinde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003; 23(25):8778–89. https://doi.org/10.1523/JNEUROSCI.23-25-08788.2003 PMID: 14507979

42. Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain. 2009; 146(3):270–5.

43. Wasserman D, Geijer T, Sokolowski M, Rozanov V, Wasserman J. The serotonin 1A receptor C(-1019)G polymorphism in relation to suicide attempt. Behavioral and brain functions: BBF. 2006; 2:14. https://doi.org/10.1186/1744-9081-2-14 PMID: 1662484

44. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science (New York, NY). 1996; 274(5292):1527–31. https://doi.org/10.1126/science.274.5292.1527 PMID: 8929413

45. Kosek E, Ekholm J, Nordemar R. A comparison of pressure pain thresholds in different tissues and body regions. Long-term reliability of pressure algometry in healthy volunteers. Scand J Rehabil Med. 1993; 25(3):117–24. PMID: 8248762

46. Kosek E, Ekholm J. Modulation of pressure pain thresholds during and following isometric contraction. Pain. 1995; 61(3):481–6. https://doi.org/10.1016/0304-3959(94)00217-3 PMID: 7478692

47. Ellerbrock I, Sandstro¨ m A, Tour J, Fanton S, Kadetoff D, Schalling M, et al. Serotonergic gene-to-gene interaction is associated with mood and GABA concentrations but not with pain-related cerebral processing in fibromyalgia subjects and healthy controls. Molecular brain. 2021; 14(1):81. https://doi.org/10.1186/s13041-021-00789-4 PMID: 33980291

48. Czesak M, Le Franç¸ ois B, Millar AM, Deria M, Daigle M, Visvader JE, et al. Increased serotonin-1A (5-HT1A) autoreceptor expression and reduced raphe serotonin levels in deformed epidermal autoregulatory factor-1 (Deaf-1) gene knock-out mice. J Biol Chem. 2012; 287(9):6615–27. https://doi.org/10.1074/jbc.M111.293027 PMID: 22232550

49. Tan EC, Lim EC, Teo YY, Lim Y, Law HY, Sia AT. Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol Pain. 2009; 5:32. https://doi.org/10.1186/1744-8069-5-32 PMID: 19545447

50. Arendt-Nielsen L, Andresen T, Malver LP, Oksche A, Mansikka H, Drewes AM. A Double-blind, Placebo-controlled Study on the Effect of Buprenorphine and Fentanyl on Descending Pain Modulation: A Human Experimental Study. The Clinical journal of pain. 2012; 28(7):623–7. https://doi.org/10.1097/AJP.0b013e31823e15cb PMID: 22156892

51. Martel MO, Petersen K, Cornelius M, Arendt-Nielsen L, Edwards R. Endogenous Pain Modulation Profiles Among Individuals With Chronic Pain: Relation to Opioid Use. The journal of pain: official journal of the American Pain Society. 2019; 20(4):462–71. https://doi.org/10.1016/j.jpain.2018.10.004 PMID: 30385319

52. Oertel BG, Doehring A, Roskam B, Kettnier M, Hackmann N, Ferreirós N, et al. Genetic-epigenetic interaction regulates μ-opioid receptor regulation. Hum Mol Genet. 2012; 21(21):4751–60. https://doi.org/10.1093/hmg/ddz314 PMID: 22875838

53. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007; 27(37):10000–6. https://doi.org/10.1523/JNEUROSCI.2849-07.2007 PMID: 17855614

54. Jensen KB, Kosek E, Petzke F, Carville S, Fransson P, Marcus H, et al. Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain. 2009; 144(1–2):95–100. https://doi.org/10.1016/j.pain.2009.03.018 PMID: 19410366

55. Schrepf A, Harper DE, Harte SE, Wang H, Ichasco E, Hampson JP, et al. Endogenous opioidergic dysregulation of pain in Fibromyalgia: a PET and fMRI study. Pain. 2016; 157(10):2217–25. https://doi.org/10.1097/j.1526-9050.2016.02850.x PMID: 27420668

56. Jensen KB, Loitoile R, Kosek E, Petzke F, Carville S, Fransson P, et al. Patients with fibromyalgia display less functional connectivity in the brain’s pain inhibitory network. Mol Pain. 2012; 8:32. https://doi.org/10.1186/1744-8069-8-32 PMID: 22537768

57. Jensen KB, Srinivasan P, Spaeth R, Tan Y, Kosek E, Petzke F, et al. Overlapping structural and functional brain changes in patients with long-term exposure to fibromyalgia pain. Arthritis and rheumatism. 2013; 65(12):3293–303. https://doi.org/10.1002/art.38170 PMID: 23982850

58. Potvin S, Larouche A, Normand E, de Souza JB, Gaumont I, Marchand S, et al. No relationship between the ins del polymorphism of the serotonin transporter promoter and pain perception in fibromyalgia patients and healthy controls. European journal of pain (London, England). 2010; 14(7):742–6. https://doi.org/10.1016/j.ejpain.2009.12.004 PMID: 20080425
59. Fields H. State-dependent opioid control of pain. Nat Rev Neurosci. 2004; 5(7):565–75. https://doi.org/10.1038/nrn1431 PMID: 15208698

60. Deseure K, Koek W, Adriaensen H, Colpaert FC. Continuous administration of the 5-hydroxytryptamine1A agonist (3-Chloro-4-fluoro-phenyl)-[4-fluoro-4-[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl] piperidin-1-yl]-methadone (F 13640) attenuates allodynia-like behavior in a rat model of trigeminal neuropathic pain. The Journal of pharmacology and experimental therapeutics. 2003; 306(2):505–14. https://doi.org/10.1124/jpet.103.050286 PMID: 12730352

61. Haleem DJ. Serotonin-1A receptor dependent modulation of pain and reward for improving therapy of chronic pain. Pharmacological Research. 2018; 134:212–9. https://doi.org/10.1016/j.phrs.2018.06.030 PMID: 29969666

62. Jeong HJ, Mitchell VA, Vaughan CW. Role of 5-HT(1) receptor subtypes in the modulation of pain and synaptic transmission in rat spinal superficial dorsal horn. Br J Pharmacol. 2012; 165(6):1956–65. https://doi.org/10.1111/j.1476-5381.2011.01685.x PMID: 21950560

63. Treister R, Pud D, Ebstein RP, Laiba E, Raz Y, Gershon E, et al. Association between polymorphisms in serotonin and dopamine-related genes and endogenous pain modulation. The journal of pain: official journal of the American Pain Society. 2011; 12(8):875–83. https://doi.org/10.1016/j.jpain.2011.02.348 PMID: 21719351

64. Lotsch J, Geisslinger G, Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacology & therapeutics. 2009; 124(2):168–84. https://doi.org/10.1016/j.pharmthera.2009.06.010 PMID: 19615406